First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

416

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
Colorectal Cancer
Interventions
DEVICE

MRD

ctDNA MRD test

Trial Locations (22)

12000

Hadassah University Hospital - Mount Scopus, Jerusalem

20089

Istituto Clinico Humanitas, Rozzano

20162

Istituto Nazionale Tumori - Fondazione G Pascale, Napoli

20262

ASST Grande Ospedale Metropolitano Niguarda, Milan

28046

Hospital Universitario La Paz, Madrid

28050

Centro Integral Oncológico Clara Campal (HM CIOCC), Madrid

64239

Tel Aviv Sourasky Medical Center, Tel Aviv Yaffo

1834111

HaEmek Medical Center, Afula

3846201

Hillel Yaffe Medical Center, Hadera

7610793

Kagawa University Hospital, Kita-gun

8410101

Soroka University Medical Center, Beersheba

9312584

Shaare Zedek Medical Center Jerusalem, Jerusalem

277-8577

National Cancer Center Hospital East, Kashiwa

003-0804

Hokkaido Cancer Center, Sapporo

OX3 7LE

Churchill Hospital, Headington

EH4 3NQ

Edinburgh Cancer Centre, Edinburgh

B15 2TH

Queen Elizabeth Hospital Birmingham, Birmingham

WR5 1DD

Worcestershire Royal Hospital, Worcester

IP4 5PD

Ipswich Hospital, Ipswich

DY11 6RJ

Kidderminster Hospital and Treatment Centre, Kidderminster

B98 7UB

Alexandra Hospital, Redditch

TQ2 7AA

Torbay Hospital, Torquay

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Fortrea

INDUSTRY

lead

Exact Sciences Corporation

INDUSTRY

NCT06398743 - First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer | Biotech Hunter | Biotech Hunter